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Abstract
Background Cocaine exposure during pregnancy has been
reported to have detrimental effects on the fetus.
Objective To describe the findings on cranial ultrasonography
(CUS) as part of a neonatal screening programme for exposed
neonates.
Materials and methods The study was a semiprospective
analysis of a 12-year cohort of neonates born to mothers
who had used cocaine during their pregnancy and who had
follow-up according to a strict clinical protocol.
Results In total, 154 neonates (78 boys, 76 girls) were
included, of whom 29 (19%) were born preterm, and 125
(81%) were born full-term. Abnormalities on CUS were seen
in 37 neonates (24%; 95% CI 18–31%). The abnormalities
were classified as minor in 20 (13%; 95% CI 9–19%) and
mildly abnormal in 17 (11%; 95% CI 7–17%). None of the
infants showed severe abnormalities. The abnormalities were
not associated with the duration or maximum amount of
cocaine use during pregnancy.
Conclusion None of the infants had severe abnormalities.
Detected abnormalities were not correlated with the
duration or maximum amount of cocaine use. Given these
findings, we feel that routine cranial ultrasonography in this
population is not warranted.
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Introduction
Since the late 1980s intrauterine cocaine exposure has been
reported to have detrimental effects on the fetus and to be a
risk for pregnancy and delivery [1, 2]. Currently, cocaine is
one of the most popular illicit drugs (besides marijuana) in
the Netherlands, being used in all socioeconomic groups.
Cocaine has been specifically implicated as a drug with
major side effects on pregnancy. In their seminal paper,
Dixon and Bejar [3] reported a sevenfold increase in
abnormalities on cranial ultrasonography (CUS) in general
and a twofold increase in the incidence of subependymal
haemorrhage (SEH) in neonates exposed to cocaine and/or
methamphetamine. In a relatively small study amongst 21
cocaine users in Amsterdam a 4.3% neonatal mortality rate
was found [4].
Cocaine has two major pharmacological effects. First, it
inhibits the reuptake of dopamine, norepinephrine and
serotonin. Second, it causes vasoconstriction. As cocaine
crosses the placenta, obstetric implications of cocaine use
have been reported. These implications are an increased
risk of placental abruption [5–7], preterm prelabour rupture
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of membranes [8], and spontaneous abortion. In the
neonate, detrimental effects on brain development have
been reported [3, 9, 10]. These effects include, amongst
others, infarction [11], subependymal cysts [12, 13],
haemorrhage, ventricular dilatation, and midline CNS
defects [11]. Besides intracranial pathology, congenital
malformations, intrauterine growth restriction [14], and
neonatal abstinence syndrome [15] have also been reported.
As a result of reports on the effect of cocaine on brain
development, the Departments of Obstetrics and Gynaecol-
ogy, Neonatology and Radiology of the Academic Medical
Center Amsterdam instituted screening CUS in neonates
with prenatal cocaine exposure. However, more recent
reviews of the literature indicated that antenatal cocaine
exposure has measurable, but not dramatic effects on infant
brain development and CUS studies [16, 17].
The aim of the present semiprospective study was to
assess the frequency and severity of abnormalities on CUS,
and to assess whether there is an association between the
maximum amount or duration of cocaine use during
pregnancy.
Materials and methods
This was a semiprospective study. Consecutive neonates
were prospectively included if maternal cocaine use
during pregnancy was reported, and CUS was retrospec-
tively analysed. The study was part of a larger semi-
prospective cohort study of maternal illicit drug users in
the greater Amsterdam region. The Department of Obstet-
rics of the Academic Medical Centre, Amsterdam, led the
study. The inclusion period for this retrospective study ran
from 1 January 1995 to 31 December 2006.
Participants
All participants enrolled in this semiprospective study
came from a cohort of consecutive neonates born between
1 January 1995 and 31 December 2006 to mothers who
used at least cocaine during pregnancy and who were
referred to our outpatient obstetric department. Women
using cannabis, opiates and methadone, and other illicit
drugs besides cocaine were not excluded. Drug use was
assessed through extensive drug history, urine screening of
the mother, and urine screening of the child. The amount
of cocaine use was scored as intermittent (i.e. not daily
during pregnancy; usually <1 g per occasion), <1 g daily,
1–4 g daily, and >4 g daily. Duration of cocaine use was
scored as only in the first trimester, in the first and second
trimesters, or throughout pregnancy.
If, in any trimester, the mother had a positive history or
positive urine test for cocaine or if the neonate had a
positive urine test for cocaine, both mother and child were
included in the study. In addition, during pregnancy women
using cocaine were structurally interviewed by the same
midwife (M.v.H.) with respect to quality and quantity of
illicit drug use and life-style in each trimester. Clinical data
were further obtained through review of medical charts of
both mothers and neonates.
In light of the question posed in this study, only those
neonates who underwent CUS and whose CUS was
considered of sufficient quality for review were analysed.
Cranial ultrasonography
CUS was performed following the standard routine in place
during the study period. Examinations were performed by
radiology residents, both with and without supervision of a
paediatric radiologist, and paediatric radiologists. CUS was
performed using a 7.5-MHz curvilinear transducer and
contemporary state-of-the-art equipment. As the studies
were performed in a clinical setting there were no specified
imaging planes.
CUS studies were retrospectively assessed by one
paediatric radiologist (R.v.R.). Although the reviewer was
aware of the fact that all studies submitted for review were
of neonates with prenatal exposure to cocaine, he was not
aware of any clinical findings, maternal nor neonatal, or
clinical outcome of the neonates.
The majority of the CUS studies were reviewed on a
PACS system (AGFA Impax 4.1 SP4 SU4; Agfa Gevaert,
Mortsel, Belgium). A minority of the studies were printed on
film and these were of technically adequate quality to review.
Intraventricular haemorrhages were graded according to
the procedure of Papile et al. [18]. Increased periventricular
echogenicity was scored as either present (periventricular
leukomalacia, PVL, grade I) or absent; cystic degeneration
was scored as either local (PVL grade II) or disseminated
(PVL grade III). Ventricular dilatation was assessed using the
Levene index in neonates up to 40 weeks’ gestational age
(GA) and using the ventricular index in older neonates [19,
20]. The scans were also re-evaluated for the presence of
lenticulostriate vasculopathy, calcifications, germinal layer
cysts, choroid plexus cysts, and subependymal pseudocysts.
CUS was scored according to procedure of Rademaker
et al. [21] and was considered to be normal when no or
minor abnormalities, such as germinal layer/plexus cysts,
subependymal pseudocysts, or calcifications as exclusive
findings were present; mildly abnormal when a haemor-
rhage grade I or II according to Papile, PVL I, or germinal
layer necrosis, or a combination of these features, was
present; and severely abnormal when one or more of the
following features were present: haemorrhage grade III or
IV according to Papile, cystic PVL II/III, thalamic lesion,
focal infarction, or convexity haemorrhage.
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Statistical analysis
Statistical analysis was performed using SPSS for Windows
12.0. (Statistical Package for the Social Sciences, Chicago,
IL). Results for normally distributed continuous variables
(birth weight, GA, etc.) are expressed as means±SD. For
the neonates, growth data at birth were analysed with the
“Kloosterman growth chart” in order to calculate the
standard deviation score (SDS) [22].
Bivariate correlations were analysed using a nonpara-
metric test. The following correlations were tested: CUS
abnormalities (classified according to Rademaker et al.
[21]) versus duration and amount of cocaine use, maternal
age, maternal education level, number of prenatal visits, co-
use of other drugs, alcohol or smoking, complications
during pregnancy (intrauterine growth retardation, pre-
eclampsia, HELLP syndrome, or premature labour), com-
plications during delivery (fetal distress, meconium-stained
amniotic fluid, premature rupture of membranes, prolonged
rupture of membranes, or perinatal infection), GA, birth
weight (in grams and expressed as SDS), sex, and 1- and 5-
min Apgar scores. P values <0.05 were assumed to reflect
statistical significance.
Ethical approval
According to Academic Medical Center guidelines for
retrospective studies, internal review board approval is not




Between 1 January 1995 and 31December 2006, 188 neonates
(97 boys, 52%; 91 girls, 48%) were born to 178 women who
had used cocaine during pregnancy. Of these women, six had
had two pregnancies, one had had three pregnancies, and two
delivered twins. The mean age of the mothers at the time of
delivery was 29.3 years (SD 6.2 years, range 18.2–42.4 years).
In 15 (8%) of the 188 neonates there was a protocol
violation as CUS was not performed. Of the remaining 173,
19 (11%) CUS studies were of insufficient quality for
review and were excluded from further analysis. Of the
examinations of insufficient quality for review, 12 were
performed by radiology residents (three, 16%, supervised
and nine, 47%, unsupervised), and seven (37%) were
performed by a radiologist. There were no significant
differences between neonates with a CUS examination
considered to be of sufficient quality for review and those
with a CUS examination considered to be of insufficient
quality for review with respect to maternal age (P=0.094),
GA (P=0.308), birth weight (P=0.226), birth weight SDS
(P=0.735), sex distribution (P=0.264), duration (P=0.298),
or amount of cocaine use (P=0.929). Review of the
radiology reports of the 19 ‘insufficient quality’ examina-
tions revealed no intracranial pathology in 15 neonates
(79%; 95% CI 56–92%), in three of which repeat CUS was
performed at respectively 1, 3 and 5 months after the initial
CUS, and these CUS were also reported to be normal. In
four neonates (21%; 95% CI 8–44%) abnormalities were
seen; in one a choroid plexus cyst and in the other three
grade 1 SEH.
In total, 154 CUS studies of good quality (82%, 78 boys
and 76 girls, born to 147 mothers) were available for
review, and were included in all further analyses.
Maternal characteristics
In 52 (34%) of the 154 pregnancies, the mother used
cocaine in the first trimester only, in 11 (7%) in the first and
second trimester only, and in 87 (56%) also during the third
trimester. Two women had a positive urine test in the third
trimester only; all other urine tests and histories were
negative for cocaine use. Two children had a positive urine
test, although the history and/or urine test of the mothers
were negative. In 25 (16%) of the pregnancies, the amount
of cocaine used by the mother was not known; in 37 (24%)
the mother used it intermittently, in 59 (38%) the mother
used <1 g daily, in 24 (16%) the mother used 1–4 g daily,
and in 9 (6%) the mother used >4 g daily.
Co-use of alcohol and nicotine was common in the study
population. Alcohol use during pregnancy was recorded in
94 women; 53 (56%) used alcohol throughout pregnancy.
Smoking during pregnancy was recorded in 137 women;
130 (95%) smoked cigarettes throughout pregnancy. Co-use
of other drugs is shown in Table 1.
Table 1 Co-use of other drugs.
Drugs used Number (%)
Cocaine only 20 (13.0)
Cocaine + cannabis 51 (33.1)
Cocaine + opiates/methadone 18 (11.7)
Cocaine + other drugs (e.g. amphetamines) 7 (4.5)
Cocaine + cannabis + opiates/methadone 16 (10.4)
Cocaine + cannabis + other drugs 19 (12.3)
Cocaine + opiates/methadone + other drugs 10 (6.5)
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Child characteristics
Nine neonates (6%; 95% CI 3–11%) were born before
33 weeks’ GA, 20 (13%; 95% CI 8–19%) between 33 and
37 weeks’ GA, and 125 (81%; 95% CI 74–87%) from
37 weeks’ GA onwards. The mean birth weight was
2,890±643 g (range 780–4,350 g); the mean birth weight
SDS was −0.62±0.89 (range −2.72 to +2.18). Of the 154
neonates, 36 (23%; 95% CI 17–31%) were small for GA
(birth weight <−1.3 SDS), and 4 newborns (3%; 95% CI 1–
7%) were large for GA (birth weight >+1.3 SDS). The
median Apgar score after 1 min was 9 (range 1–10) and
after 5 min was 10 (range 4–10). There were no neonatal
deaths in our study cohort (two fetal deaths at 35 and
36 weeks are not included).
Cranial ultrasonography
Cranial ultrasonography was performed by radiology
residents in 79 cases (51%), in 37 cases with supervision,
and in 42 cases without supervision; the remaining 75 CUS
(49%) were performed by radiologists. CUS was performed
on average on day 4 (range 0–76). Thirty-seven out of 154
sufficient-quality CUS (24%; 95% CI 18–31%) showed
abnormalities on the CUS. Seven of these neonates were
born at a GA of ≤32 weeks (19%; 95% CI 9–35%),
8 between 33 and 37 weeks (22%; 95% CI 11–37%) and 22
full term (60%; 95% CI 43–74%).
Table 2 shows the abnormalities on CUS for three GA
groups. In total there were 16 grade I SEH in 13 neonates.
Of these 13 neonates, 8 (22%; 95% CI 11–37%) showed
unilateral grade 1 SEH and 2 (5%; 95% CI 1–19%) showed
bilateral grade 1 SEH. One neonate (3%; 95% CI 0–15%)
showed a right-sided grade 2 SEH and a left-sided grade 1
SEH. Two neonates (5%; 95% CI 1–19%) showed cystic
(old) SEH, one of them bilateral. In 13 out of 37 neonates
(35%; 95% CI 22–51%) a choroid plexus cyst was recorded
on CUS. Three neonates had a subependymal cyst (8%;
95% CI 2–22%). Five neonates showed increased periven-
tricular echogenicity (14%; 95% CI 5–28%), two of them
bilateral. Three neonates had unilateral lenticulostriate
vasculopathy (8%; 95% CI 2–22%), and in five it was
bilateral (14%; 95% CI 5–28%). One neonate (3%; 95% CI
0–15%) showed mild bilateral ventricular dilatation without
other abnormalities.
Applying the criteria of Rademaker et al. [21], the
abnormalities could be classified as minor in 20 (13%;
95% CI 8–19%) neonates and mildly abnormal in 17 (11%;
95% CI 7–17%). None of the infants showed severe
abnormalities.
Bivariate correlations showed that neither the duration
nor the maximum amount of cocaine use during pregnancy
was correlated with CUS abnormalities (Table 3). In
addition, co-use of other drugs, alcohol use, or cigarette
smoking did not correlate with CUS abnormalities. CUS
abnormalities were found more frequently with fewer
prenatal visits after 20 weeks’ GA, in complicated
pregnancies, shorter duration of GA, and lower absolute
birth weight (Table 3).
Table 2 Distribution of pathology found on routine CUS screening in








Grade 1 6 2 8
Grade II 1 0 0
Choroid plexus cyst
Unilateral 1 4 8
Bilateral 0 0 0
Subependymal cyst 1 0 2
Periventricular echodensity
Unilateral 1 1 1
Bilateral 1 0 1
Lenticulostriate vasculopathy
Unilateral 0 1 2
Bilateral 0 0 5
Total 11 8 27
Rademaker score
Minor 0 5 15
Mild 7 3 7
Table 3 Correlations with abnormal CUS findings.
R P
Duration of cocaine use +0.038 0.642
Maximum amount of cocaine use +0.018 0.821
Maternal age +0.089 0.271
Maternal education level −0.121 0.167
Number of prenatal visits before 20 weeks’ GA −0.081 0.333
Number of prenatal visits after 20 weeks’ GA −0.220 0.006
Co-use of cannabis and/or opiates −0.101 0.213
Alcohol −0.075 0.354
Smoking −0.048 0.557
Complications during pregnancya −0.226 0.005
Complications during deliveryb −0.109 0.179
Gestational age (weeks) −0.488 <0.001
Birth weight (g) −0.404 <0.001
Birth weight SDS −0.052 0.521
Sex +0.025 0.755
Apgar scores
1 min −0.039 0.640
5 min −0.039 0.635
a Intrauterine growth retardation, preeclampsia, HELLP syndrome, or
premature labour.
b Fetal distress, meconium-stained amniotic fluid, premature rupture of
membranes, prolonged rupture of membranes, or perinatal infection.
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Discussion
Neonatal congenital anomalies seen on CUS have been
related to prenatal cocaine exposure [13, 23, 24]. In our
study population 24% of the neonates with antenatal
cocaine exposure showed abnormalities on CUS. Although
this seems high, it must be noted that all abnormalities
could be classified as minor (13%) or mild (11%); none of
the infants had severe CUS abnormalities. In addition, CUS
abnormalities were not correlated with the duration or
maximum amount of cocaine use.
The literature shows conflicting data with regard to
prenatal cocaine exposure in relation to CUS findings.
Smith et al. [13] found an increased incidence of sub-
ependymal cysts in neonates with prenatal cocaine expo-
sure compared to non-exposed neonates (44% vs. 8%,
P<0.01) [13]. Dogra et al. [9] found abnormalities on CUS
in 14 of 40 (35%) neonates, with prenatal cocaine exposure,
whereas their age-matched control group showed no
abnormalities on CUS. The main findings were focal
echolucencies (i.e. cystic lesions) and increased echogenic-
ity of the caudate nucleus.
In a study by King et al. [25], however, no significant
difference was found between exposed neonates (incidence
24%) and non-exposed neonates (incidence 34%) with
respect to abnormalities found on CUS. These findings are
supported by Bauer et al. [15] who compared CUS in 132
exposed neonates to 711 non-exposed neonates. In
the exposed group 29.5% of the neonates and in the non-
exposed groups 30.8% of the neonates showed abnormal-
ities on CUS. As part of the only prospective longitudinal
study published to date, 154 cocaine users were matched to
154 control subjects; no significant difference between
these groups in the incidence of abnormal CUS (13% in
exposed vs. 8% in non-exposed neonates) was found [26].
Furthermore, the authors specifically stated that the identi-
fied lesions were less severe than previously reported.
There are few data on the influence of the level of
cocaine exposure on CUS abnormalities. Only one study
assessed a dose-effect relationship between prenatal cocaine
exposure and CUS findings [27]. They showed that infants
with heavier cocaine exposure were more likely to show
SEH than lighter or unexposed infants (adjusted odds ratio
3.88; 95% CI 1.45–10.35). This is in contrast to our results.
We performed a subgroup analysis, but this also did not
reveal a correlation between SEH and the maximum
amount or duration of cocaine use in pregnancy.
An important factor that has received relatively little
attention is the relationship between neonatal CUS findings
and neurobehavioural outcome in (near-)term infants with
antenatal cocaine exposure. Behnke et al. [28] studied 266
infants, both with and without prenatal exposure to cocaine,
who underwent CUS within the first 96 h after birth. There
were 239 normal examinations and 27 abnormal examina-
tions. Based on the Amiel-Tison neonatal neurological
assessment, performed within 96 h, there was no significant
difference between the two groups. Neurodevelopmental
outcome has been studied in preterm infants who under-
went screening CUS. Rademaker et al. [21] studied a 2-year
cohort of 221 preterm infants and related neonatal CUS
findings to school performance. Children with normal or
mildly abnormal CUS had similar mean IQ values and the
proportion of children with an IQ ≤85 was not different
between these CUS groups. Pisani et al. [29] followed 78
preterm infants without CUS abnormalities and 50 preterm
infants with transient periventricular echodensities up to the
age of 12 months [29]. At 12 months, 88.5% of the first
group and 94% of the second group showed normal
neurodevelopment. They concluded that the two groups
showed identical outcomes with regard to neurodevelop-
ment. In a study by Stewart et al. [30] of very preterm
neonates, 5 of 62 infants (8%) with normal CUS and 2 of
25 infants (8%) with uncomplicated periventricular hae-
morrhage showed neurological or developmental sequelae
at 18 months of age.
As in all clinical studies with drug abusers, confounding
factors are abundant. In general, socioeconomic status is
lower than in the general population. In The Netherlands
we generally have a more liberal approach to illicit drug
use, which allows early medical support and intervention
during pregnancy. This might reduce this effect somewhat.
A second confounding factor is the co-use of nicotine,
alcohol and other illicit drugs besides cocaine. Teratogenic
effects on the developing brain have been described in
maternal nicotine and alcohol use. In case of maternal
nicotine use, a study in rats has shown that on a cellular
level nicotinic cholinergic receptor expression is altered
[31]. However, in these cases no gross developmental
abnormalities have been described. In prenatal alcohol
exposure a reduction in the frontal cortex has been
described. This study using CUS as the imaging modality
does not allow evaluation of this anomaly [32].
As this was a semiprospective study it had inherent
drawbacks. First, US is an operator-dependent technique
that makes review a difficult task. Over time, different US
systems have been used in our hospital, all reflecting the
state-of-the-art at the time of use. As the studies were
performed in a clinical setting there were no specified
imaging planes for CUS. This led to 19 examinations,
containing only a limited number of images, being regarded
as inadequate for inclusion in the study. The authors
assumed that if at the time of the examination an
ultrasonographer had seen an abnormality he/she would
likely have stored more images than in an otherwise normal
study. Based on this assumption a separate analysis of the
US reports in these 19 neonates was performed. This
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showed that exclusion of these cases introduced no bias
into our study.
A second drawback is the lack of a control group. We
did not attempt to include a control group because we felt it
was impossible to compose a group that was completely
comparable, especially in life-style and socioeconomic
background, to drug users. We therefore had to compare
our findings to the findings reported in the literature. Third,
it is well known that reliable assessment of drug use is
extremely difficult. This obviously has implications for the
evaluation of a dose-effect relationship.
Our findings on the occurrence of CUS abnormalities
after prenatal cocaine exposure are in keeping with previ-
ously published papers [15, 25, 26]. However, it is known
that at a later age children with prenatal cocaine exposure
may show neurocognitive development disorders. To
further study these effects of prenatal cocaine exposure at
a later age functional MRI in exposed adolescents, matched
to a non-exposed population, would be worth considering.
Although the frequency of CUS abnormalities seems to
be high in our study population (around a quarter of the
neonates), it corresponds with non-exposed infants in recent
reports in the literature. All abnormalities were classified as
minor or mild and would probably have no long-term
consequences for neurodevelopment. In addition, abnor-
malities detected with CUS were not correlated with the
duration or maximum amount of cocaine use. In spite of the
semiprospective nature of our study, we feel on the basis of
our findings, in combination with data presented in the
literature, that CUS screening in this specific population is
not warranted.
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